PMID- 28214955
OWN - NLM
STAT- MEDLINE
DCOM- 20170913
LR  - 20220318
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 255
IP  - 6
DP  - 2017 Jun
TI  - Ranibizumab versus aflibercept for macular edema due to central retinal vein 
      occlusion: 18-month results in real-life data.
PG  - 1093-1100
LID - 10.1007/s00417-017-3613-1 [doi]
AB  - PURPOSE: The objective of this study was to compare the anatomical and functional 
      outcomes of ranibizumab versus aflibercept for the treatment of macular edema due 
      to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: 
      Participants in this observational study included 62 treatment-naive patients 
      with CRVO who received intravitreal injections of either ranibizumab or 
      aflibercept. The demographic data, best-corrected visual acuity (BCVA) and 
      spectral-domain optical coherence tomography (SD-OCT) characteristics were 
      evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment. 
      RESULTS: At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 
      letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar 
      number of injections. There was no statistically significant difference between 
      the two groups in letters or in central subfield thickness at month 18. At the 
      end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the 
      aflibercept group showed complete resolution of macular edema. CONCLUSIONS: 
      Ranibizumab and aflibercept demonstrated similar anatomical and functional 
      outcomes over 18-month follow-up in patients with macular edema due to CRVO, with 
      a similar number of injections.
FAU - Chatziralli, Irini
AU  - Chatziralli I
AD  - 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, 
      Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece. eirchat@yahoo.gr.
FAU - Theodossiadis, George
AU  - Theodossiadis G
AD  - 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece.
FAU - Moschos, Marilita M
AU  - Moschos MM
AD  - 1st Department of Ophthalmology, University of Athens, Athens, Greece.
FAU - Mitropoulos, Panagiotis
AU  - Mitropoulos P
AD  - 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
FAU - Theodossiadis, Panagiotis
AU  - Theodossiadis P
AD  - 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, 
      Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170218
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
CIN - Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255 (7):1455-1457. PMID: 28470435
CIN - Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255 (7):1459-1460. PMID: 28484833
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Intravitreal Injections
MH  - Macular Edema/diagnosis/*drug therapy/etiology
MH  - Prospective Studies
MH  - Ranibizumab/*administration & dosage
MH  - Receptors, Vascular Endothelial Growth Factor/*administration & 
      dosage/antagonists & inhibitors
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Retinal Vein Occlusion/complications/diagnosis/*drug therapy
MH  - Time Factors
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - *Visual Acuity
OTO - NOTNLM
OT  - Aflibercept
OT  - Central subfield thickness
OT  - Optical coherence tomography
OT  - Ranibizumab
OT  - Retinal vein occlusion
OT  - Visual acuity
EDAT- 2017/02/20 06:00
MHDA- 2017/09/14 06:00
CRDT- 2017/02/20 06:00
PHST- 2016/10/27 00:00 [received]
PHST- 2017/02/06 00:00 [accepted]
PHST- 2017/01/18 00:00 [revised]
PHST- 2017/02/20 06:00 [pubmed]
PHST- 2017/09/14 06:00 [medline]
PHST- 2017/02/20 06:00 [entrez]
AID - 10.1007/s00417-017-3613-1 [pii]
AID - 10.1007/s00417-017-3613-1 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1093-1100. doi: 
      10.1007/s00417-017-3613-1. Epub 2017 Feb 18.